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Abstract
Colorectal cancer is the third most common malig-
nancy in the United States. Improved detection
sensitivity of early colorectal neoplasms would have
important clinical applications. Herein, we report on
using phage display to generate peptide libraries that
detect colon carcinoma tissues. To accomplish this,
we employed positive selection of a peptide-bearing
phage library on poorly differentiated colon carcinoma
cells (HT29) and combined this with negative selection
of the phage library on well-differentiated colon
carcinoma cells (HCT116). Analysis of the resulting
library identified a nine-amino-acid, disulfide-con-
strained peptide, CPIEDRPMC (RPMrel), that stained
HT29 colon carcinoma cells. Immunohistochemical
staining using FITC-conjugated RPMrel peptide also
showed binding of RPMrel to colon tumor tissues from
four patients. We saw no binding of RPMrel to normal
colon tissues. In addition, RPMrel failed to stain a
panel of noncolon tissues including the lungs, liver,
and stomach. We further demonstrated that RPMrel
coupled to the mitochondrial toxin (KLAKLAK)2 killed
HT29 cells. These studies suggest that RPMrel may be
a promising lead candidate in the development of a
useful colon tumor diagnostic and targeted drug
delivery agent.
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Introduction
Colon carcinogenesis is thought to emerge through a
stepwise process that involves the transition of normal
colon epithelium to neoplasm [1]. Themultistep progression
of the disease requires years and possibly decades, thus
seeming to provide ample time for diagnosis and treatment.
Unfortunately, 57% of colon cancers remain undetected
until it has spread to the surrounding organs or lymph, a
finding that correlates with poor prognosis [2]. Improve-
ments in patient survival could potentially come by diag-
nosing colon cancer at earlier stages.
The past decade has seen an explosion in our knowl-
edge of the genetic events that accompany the progression
of normal colonic epithelium to neoplasm. For example, in
approximately 85% of sporadic colon cancers and all cases of
the inherited colon disease, familial adenomatous polyposis
(FAP), the adenomatous polyposis coli (apc) gene is mutated
[3]. Although underlying molecular causes of colon cancer have
been identified, this knowledge has translated into modest
clinical success in the early diagnosis and treatment of colon
cancer [2]. This may be explained, in part, by the observation
that conventional screening methods are limited by their sen-
sitivity. Endoscopic techniques, which are the most sensitive
diagnostic methods, are limited in sensitivity because detection
of colon cancer is limited to lesions the examiner can visualize
[4]. In view of this, screening methods that could conveniently
detect colon neoplasms at earlier stages could have an impor-
tant clinical impact.
Early work to develop better diagnostic and therapeutic
molecules has focused on the use of antibodies for tumor
recognition and drug delivery [5,6]. However, when antibodies
are used as the targeting molecule, the immunogenicity and
long plasma half-life of these proteins are detrimental [7]. The
use of small peptides may circumvent these shortcomings
because they are typically nonimmunogenic and combine high
affinity and selectivity with more desirable pharmacokinetic
properties. Furthermore, specific targeting of tumor cells using
high-affinity and highly selective peptides conjugated to con-
ventional chemotherapeutics enables the use of low doses,
eliminating the toxic effects of chemotherapeutics such as
doxorubicin [8].
The display of peptide libraries on the surface of bacterio-
phage offers a way of searching for peptides with specific
binding properties [9]. The traditional and most widespread
use of phage display is to identify peptides that bind to
homogenous, purified target proteins [10–12]. In order to
identify potential diagnostics and therapeutics for colon cancer,
we have used phage display to generate peptide libraries that
distinguish between comparatively well-differentiated
(HCT116) [13] and poorly differentiated, highly tumorigenic
colon carcinoma cells (HT29) [14]. Using a method of selection
and subtraction, we have isolated peptides that display a
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consensus motif, RPMC, and bind to HT29 cells in compar-
ison to HCT116 cells. The CPIEDRPMC (RPMrel) peptide
also showed binding to five colon cancer cell lines: HT29,
CaCo-2, RKO, SW480, and DLD-1. Furthermore, fluoresce-
in-conjugated RPMrel peptide stained ex vivo tissue sections
from colon adenocarcinoma but not from normal colon,
lungs, lung sarcoma, liver, liver sarcoma, or stomach. Final-
ly, when conjugated to amitochondrial toxin, RPMrel induced
the death of HT29 cells but not HCT116 cells.
Materials and Methods
Cell Culture
All cells were obtained from the American Type Culture
Collection (Rockville, MD). HT29 and HCT116 cell lines were
maintained in McCoy’s medium supplemented with 10% fetal
bovine serum (FBS), 2 mM L-glutamine, and 1 mM sodium
pyruvate at 37jC in 5% CO2. CaCo-2 cells were maintained
in MEM supplemented with 20% FBS, 2 mM glutamine, 0.1
mM nonessential amino acids, and 1.5 g/l sodium bicarbon-
ate. For routine maintenance, CaCo-2 cells were passaged
by trypsinization immediately upon reaching confluence. For
spontaneous differentiation, the time when cells first reached
100% confluence was designated day 0 (undifferentiated).
Cells were fed fresh media every 3 days until 20 days after
reaching 100% confluence (day 20; differentiated). DLD-1
and RKO cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% FBS, 2
mM L-glutamine, and 1 mM sodium pyruvate at 37jC in 5%
CO2. Finally, SW480 cells were maintained in Leibovitz’s
L-15 medium supplemented with 10% FBS, 2 mM L-gluta-
mine, and 1 mM sodium pyruvate at 37jC in 5% CO2.
Generation of HS-1
An aliquot (10 ml) of the PhD-CX7C complete phage library
from NEB (Beverly, MA) was incubated with 2  105 HT29
cells at 4jC for 45 minutes in phosphate-buffered saline
(PBS) with 0.5% bovine serum albumin (BSA; binding buff-
er). After incubation, cells were washed with PBS/0.5% BSA/
0.05% Tween (wash buffer) for a total of six washes. Phage
that bound were eluted with 0.2M glycine (pH 2.2) for
8 minutes then neutralized with 50 ml of 1 M Tris–HCl (pH
9.0). This was selection round 1 on HT29 cells. After elution,
phage were precipitated by PEG–NaCl then resuspended in
300 ml of binding buffer. In order to subtract phage that bound
to identical markers present on both cells, the phage pool
isolated after one round of selection was subtracted by five
rounds of successive incubation with 2.0  105 HCT116
cells at 4jC for 45 minutes (steps 2–6). The phage that
bound to the HT29 cells but did not bind to the HCT116 cells
were amplified (step 7) then incubated with 2  105 HT29
cells, as above. Cells were washed to remove unbound
phage and the bound phage eluted. The number of phage
bound was determined and the remaining eluate was ampli-
fied. The selection process consisting of binding, washing,
elution, and amplification was repeated (steps 9–12) for a
total of five rounds of selection. After the five rounds of
selection, the phage pool derived from each round of selec-
tion was titered, plaques were picked, and phage DNA was
amplified by polymerase chain reaction (PCR) and, finally,
sequenced. Primers for PCR are the same as quantitative
polymerase chain reaction (Q-PCR).
Selectivity Curves
HT29 or HCT116 cells were incubated with 1010 plaque-
forming units (PFU) of phage amplified after each round of
selection for 45 minutes at 4jC. After incubation, cells were
washed six times with wash buffer. Phage were eluted at
room temperature into 300 ml of acidified buffer (0.2M gly-
cine, pH 2.2) then neutralized with 50 ml of 1 M Tris–HCl, pH
9.0. The number of phage eluted was quantified by counting
phage plaques generated by a plaque-forming assay.
Synthesis of Peptides
Peptides were synthesized using standard protected
FMOC chemistry (ABI-431; Applied Biosystems, Foster City,
CA) and purified by reverse-phase high-performance liquid
chromatography (HPLC) to >95% purity. The carboxy termi-
nus was amidated and the peptide was diluted to 0.3 mM/ml
in water adjusted to pH 8 by ammonium bicarbonate and
Tris. The peptide was oxidized by flowing air through the
diluted peptide for 2 days. After oxidation, the peptide was
lyophilized, solubilized in 0.1% TFA, and purified again by
reverse-phase HPLC. Fractions were analyzed by mass
spectrometry, reaction with Ellman’s reagent (Pierce,
Woburn, MA), and detection of shift in reverse-phase reten-
tion time [15].
Phage Competition Assays
HT29 cells were incubated with the indicated peptide in
binding buffer at concentrations of 0, 0.1, 1, 10, 100, or
1000 mM for 30 minutes at 4jC. After 30 minutes of
incubation, 1010 PFU of phage was added to the cells
and incubated at 4jC for an additional 45 minutes. Follow-
ing incubation, cells were washed six times with wash
buffer and the phage remaining bound were eluted with
0.2 M glycine, pH 2.2, then neutralized with 1 M Tris–HCl,
pH 9.0. The number of phage eluted after washing was
quantified by Q-PCR (Roche, Basel, Switzerland) [percent-
age of phage binding = (number of phage bound in the
presence of peptide competitor/number of phage bound in
the absence of peptide competitor)  100%].
Q-PCR
Q-PCR was performed according to the manufacturer’s
instructions (Roche). Data were analyzed using Light Cycler
Data Analysis version 3.0:
Primers: 5V-TTA TTC GCA ATT CCT TTA GTG-3V
5V-GCC CTC ATA GTT AGC GTA ACG-3V.
Immunocytochemistry Using FITC–RPMREL Peptide
HT29, HCT116, or a 50% mixture of HT29 and HCT116
cells was plated on glass slides (Nalge, Rochester, NY).
Wells were incubated with 10 mM FITC–RPMrel peptide for
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45 minutes at 4jC or 37jC. After washing with wash
buffer, cells were fixed with 2% paraformaldehyde then
blocked with 3% NGS, 1% BSA, and 0.1% Triton X-100 in
PBS. Following the blocking step, wells were incubated
with the p53 antibody, D01 (Santa Cruz Biotechnology,
Santa Cruz, CA), for 1 hour at room temperature. The wells
were washed and incubated with the secondary antibodies
GaFITC Alexa 488 (green) (Molecular Probes, Eugene, OR)
and GaMouse Alexa 568 (red) (Molecular Probes) and the
nuclear stain Topro-3 (blue) (Molecular Probes). Wells were
washed and mounted using Pro-Long Anti-Fade (Molecular
Probes). Slides were analyzed by confocal microscopy us-
ing  60 oil objective (Olympus, Melville, NY).
Immunocytochemistry Using CPIEDRPMC
Displaying Phage
Undifferentiated CaCo-2 cells were plated on glass slides
(Nalge). Wells were incubated with RPMrel displaying
phage, as described above. After incubation, cells were
washed then fixed with 2% paraformaldehyde. Fixed cells
were blocked with 3% NGS, 1% BSA, and 0.1% Triton X-100
in PBS then incubated with 1:500 dilution of Rabbit a M13
antisera (Stratagene, La Jolla, CA) for 1 hour at room
temperature. Cells were then washed and incubated with
GaRabbit Alexa 488 (Molecular Probes) and Topro-3 (Mo-
lecular Probes) for 1 hour at room temperature. After incu-
bation, cells were washed then slides were mounted using
Pro-Long Anti-Fade mounting medium (Molecular Probes).
Primary Tissue Analysis
Biopsies of sporadic colon adenocarcinoma, liver and
lung sarcoma, and grossly uninvolved colon, liver, lung,
and stomach were frozen in optimum cutting temperature
(OCT). For analysis, OCT frozen tissues were sliced 5 mm
thick and placed on glass slides. Sections were stained with
H&E and untreated adjacent sections were incubated with 10
mM FITC–RPMrel in binding buffer. After incubating with
FITC–RPMrel for 45 minutes at 4jC, slides were washed
and mounted using Pro-Long Anti-Fade (Molecular Probes).
Nuclei were visualized by a quick incubation with Topro-3
(Molecular Probes) present in the last wash. Fluorescent
samples were analyzed by confocal microscopy with
60  objective (Olympus). H&E-stained sections were ana-
lyzed by light microscopy with  10 objective (Olympus).
RPMrel-D(KLAKLAK)2 and D(KLAKLAK)2 on HT29 and
HCT116 Cells
HT29 and HCT116 cells were incubated with increasing
log concentrations of RPMrel-D(KLAKLAK)2 or D(KLA-
KLAK)2 in media for 72 hours at 37jC. After incubation,
MTT was added to a final concentration of 2.5 mg/ml and
incubated at 37jC for 1 hour. The media/MTT was removed
carefully and the cells dissolved with 0.1 N HCl in isopropa-
nol. Absorbance was read on a plate reader (Cytofluor II;
Perceptive Biosystems, Albertville, MN) at 570 nm.
Results
In order to identify potential molecular markers of colorectal
cancer, we have used peptide phage display. An M13
random, disulfide-constrained, peptide phage display library
with the amino acid formula CX7C was screened using the
human colon cancer cell line HT29 (see Materials and
Methods section). The use of positive and negative selection
techniques led to the generation of a library, termed HS-1,
that binds to the highly tumorigenic HT29 colon carcinoma
cells but binds poorly to well-differentiated HCT116 colon
carcinoma cells (Figure 1A). A constant number of phage
from the amplified pool of each selection round was incubat-
ed with HT29 or HCT116 cells. Following incubation, un-
bound phage were removed by washing and the phage
remaining were eluted. We then quantified the number of
phage eluted by counting PFU. After the initial round of
maturation and subtraction, the numbers of phage binding
to HT29 and HCT116 cells were equivalent (Figure 1A).
Following amplification and the second round of selection,
a two-fold selectivity of the library for HT29 cells was evident.
Maximum selectivity (10-fold) of the library for HT29 cells
occurred after the third round of selection and did not
increase with further selection steps (Figure 1A).
Because HS-1 bound preferentially to HT29 cells, we
wanted to identify the phage-displayed peptide sequences
that conferred this selectivity. To accomplish this, 30 individ-
ual phage plaques from selection rounds 1 to 4 were isolated
and the DNA from each plaque was amplified by PCR. We
then sequenced the PCR products and translated the
corresponding peptide sequences electronically. Alignment
of the 30 sequences examined from both rounds 1 and 2
showed the lack of a consensus sequence and suggested
that the initial random library contained no sequence bias. In
contrast, similar sequencing of phage from rounds 3 and 4
revealed the emergence of a clear consensus motif. In these
rounds, the majority (19/25 and 20/27) expressed an identi-
cal peptide motif, RPM (Figure 1B). Of the sequences
examined, the RPM amino acid sequence was always found
directly adjacent to the C-terminal cysteine. In addition, the
RPM motif was found in peptides with divergent sequences
in positions 1 to 4 of the displayed peptide, indicating that the
functional sequencemay be RPMC. Although round 2 did not
have a clear consensus sequence, retrospective examina-
tion showed that it did contain four phage that expressed the
RPMC motif (Figure 1B).
The enrichment of peptides with the RPMC sequence
suggested that binding to HT29 cells depended on the
peptide displayed by the phage and not on an incidental
property of the phage. To determine whether CPIEDRPMC
displaying phage bound to HT29 cells because of the dis-
played peptide, a competition assay was performed using
phage and synthetic peptides. Peptides corresponding to the
sequence [CPIEDRPMC (RPMrel)] and the unrelated se-
quence [CKHLGPQLC (RPMunrel)] were synthesized.
CKHLGPQLC was isolated from a previous screen for pep-
tides that bind to HT29 cells (data not shown). HT29 cells
were incubated with increasing concentrations of
CPIEDRPMC peptide and with a constant number of phage
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displaying either RPMrel or RPMunrel (Figure 2A). The
number of phage binding to the HT29 cells was quantified
and the percentage binding was calculated based on the
number of phage that bind in the absence of competitor.
RPMrel peptide competed with phage displaying the se-
quence CPIEDRPMC for binding to HT29 cells (Figure 2A).
In contrast, RPMrel peptide did not compete with phage
displaying the RPMunrel sequence for binding to HT29 cells.
The RPMrel peptide competitor reduced the level of
CPIEDRPMC phage-associated binding to HT29 cells to
less than 4%, whereas the level of CKHLGPQLC phage
binding to HT29 cells remained constant at 100% in the
presence of RPMrel peptide competitor (Figure 2A). In
addition, HT29 cells were incubated with increasing concen-
trations of RPMrel or RPMunrel peptide, and a constant
concentration of phage displaying the peptide CPIEDRPMC.
We obtained results similar to those presented in Figure 2A
in that RPMrel was able to compete phage bearing the same
peptide sequence, but the peptide sequence RPMunrel
failed to do so (data not shown).
Next, we wanted to determine whether RPMrel was able
to distinguish HT29 cells from HCT116 cells that were
cocultured. In order to distinguish HT29 from HCT116 cells
in our immunohistochemical assays, we stained for the
presence of the transcription factor, p53. Staining for p53
would be a way to visually discriminate HT29 from HCT116
cells because p53 is mutated and accumulates in HT29 cells
but is wild type in HCT116 cells and thus is rapidly degraded.
As we predicted, immunohistochemical analysis of HT29 and
HCT116 cells for p53 demonstrated a differential staining of
Figure 1. The HT29 mature phage pool, HS-1, binds to HT29 cells and contains a consensus motif. (A) HT29 or HCT116 cells were incubated with 1010 PFU from
the amplified phage pool generated from each round of maturation: (n) HT29 cells; (E) HCT116 cells. After incubation, the cells were washed and the phage
remaining bound were eluted into an acidified buffer. The number of phage eluted into the acidic buffer was quantified by Q-PCR. (B) RPM evolved by maturation
on HT29 cells. Sequencing of phage from each round of maturation on HT29 cells was performed as described in Materials and Methods section.
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HT29 and HCT116 cells with high levels of p53 expression
detected in HT29 cells (Figure 2B). We also stained HT29
and HCT116 cells with RPMrel conjugated to fluorescein
(FITC–RPMrel). After incubation for 1 hour at 4jC with
FITC–RPMrel, we observed fluorescence of the HT29 cells
but not of the HCT116 cells (Figure 2B). When a mixture of
HT29 and HCT116 cells was incubated with FITC–RPMrel
and concurrently analyzed for the presence of p53, cells with
the highest level of p53 protein also bound FITC–RPMrel
(Figure 2B). To determine whether FITC–RPMrel binding to
HT29 cells was dependent on the peptide sequence, a
competition experiment was performed. When HT29 cells
were incubated with FITC–RPMrel and excess unlabeled
RPMrel peptide, the unlabeled RPMrel peptide competitor
abolished FITC–RPMrel staining of HT29 cells. In contrast,
when HT29 cells were incubated with FITC–RPMrel and
excess unlabeled RPMunrel peptide, FITC–RPMrel binding
to HT29 cells was unaffected by the presence of RPMunrel
peptide (Figure 2C).
We wanted to determine whether RPMrel binding was
limited to HT29 cells. To accomplish this, we incubated 1010
PFU of RPMrel displaying phage with HT29, DLD-1, SW480,
RKO, CaCo-2 D0(undifferentiated), CaCo-2 D20 (differenti-
ated), and HCT116 colon cancer cell lines, and quantified the
Figure 2. RPMrel peptide binds to HT29 cells over HCT116 cells. (A) HT29 cells were incubated with 1010 PFU of either CPIEDRPMC (RPMrel) or CKHLGPQLC
(RPMunrel) phage and the indicated concentration of RPMrel peptide. After washing and elution into glycine buffer, pH 2.2, the number of phage was determined
by Q-PCR: (n) RPMrel displaying phage; (E) RPMunrel displaying phage. (B) Chamber slides seeded with (a) 100% HT29, (b) 100% HCT116, or (c) a 50%
mixture of HT29 and HCT116 cells were incubated with FITC–RPMrel. After incubation with FITC–RPMrel, the cells were washed, fixed, and then incubated with
a monoclonal antibody to p53. Cells were again washed then incubated with GaFITC Alexa 488 (green), GaM Alexa 568 (red), and Topro-3 (blue). Slides were
analyzed by confocal microscopy (scale bar, 20 m). (C) HT29 cells were incubated with FITC–RPMrel in the presence of excess unlabeled RPMrel or unlabeled
RPMunrel competitor, washed, fixed, incubated with GaFITC Alexa 488 (green) and Topro-3 (blue), and then analyzed by confocal microscopy (scale bar, 5.0 m).
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number of phage bound as before. Phage displaying the
RPMrel peptide bind maximally to HT29 cells and poorly to
differentiated CaCo-2 (D20) and HCT116 cells (Figure 3).
Binding of CPIEDRPMC displaying phage to DLD-1, SW480,
RKO, and undifferentiated CaCo-2 (D0) cells was slightly
lower than binding to HT29 cells (Figure 3).
Based on the binding of RPMrel peptide to HT29 cells and
its ability to bind to more than one colon cancer cell line, we
reasoned that RPMrel would bind colon tumor tissues but not
adjacent normal colon. We, therefore, determined whether
RPMrel differentially stained human colon adenocarcinoma
as opposed to normal colon. Immunohistochemical analysis
with FITC–RPMrel performed on frozen sections prepared
from biopsy samples of human colon adenocarcinoma and
grossly uninvolved normal colon showed the preferential
Figure 4. FITC–RPMrel binds to human colon tumor. (A) Frozen serial sections of matched human (a and c) colon adenocarcinoma or (b and d) normal colon were
incubated with the indicated reagent then analyzed by (a and b) H&E light microscopy and (c and d) fluorescence confocal microscopy (scale bar: a and b, 80 m; c
and d, 20 m). (B) Cryostat sections prepared from human colon tumor biopsies were incubated with FITC–RPMrel in the presence of excess unlabeled RPMrel or
unlabeled RPMunrel peptide competitor then analyzed by confocal microscopy (scale bar, 20 m) (C, a and b) Grossly uninvolved liver; (c and d) liver sarcoma; (e
and f) grossly uninvolved lung; (g and h) lung sarcoma; (i and j) normal stomach; (k and l) colon tumor. (b, d, f, h, j, and l) Fluorescence microscopy of indicated
tissues incubated with RPM–FITCrel and Topro-3 (scale bar, 20 m). (a, c, e, g, i, and k). H&E staining of corresponding views (scale bar, 80 m).
Figure 3. CPIEDRPMC peptide displaying phage bound to HT29, CaCo-2
(D0 or undifferentiated), DLD-1, SW480, and RKO but not to HCT116 or
CaCo-2 (D20 or differentiated) colon cancer cell lines. 1010 PFU of phage
displaying the CPIEDRPMC peptide was incubated with the indicated colon
cancer cell lines. The number of phage that bound to each cell line was
quantified by a plaque-forming assay.
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binding of FITC–RPMrel to human colon tumors (Figure 4A).
FITC–RPMrel stained tumors from four different patients
with a staining pattern similar to that shown in Figure 4A
(data not shown). The binding of FITC–RPMrel to colon
tumor was mediated by the peptide because unlabeled
RPMrel abolished FITC–RPMrel binding to colon tumor
(Figure 4B).
To determine whether FITC–RPMrel was able to bind
cancers originating from tissues other than the colon or to
other normal tissues, immunohistochemical analysis was
performed on cryostat sections of lung and liver cancers,
as well as grossly uninvolved lung, liver, and stomach. As a
positive control, a section of the colon tumor was stained in
parallel with other sections. Figure 4C shows that lung and
liver tumors as well as grossly uninvolved lung, liver, and
stomach showed no labeling with FITC–RPMrel. In contrast,
the colon tumor exhibited bright staining when incubated with
FITC–RPMrel.
The translocation of a molecule across the plasma mem-
brane is important for drug delivery [16]. Therefore, we
wanted to test whether HT29 or HCT116 cells internalized
FITC–RPMrel. HT29 and HCT116 cells were incubated for 1
hour at either 4jC or 37jC in the presence of 100 mM FITC–
RPMrel. After incubation, cells were washed, fixed with 2%
paraformaldehyde, and incubated with an anti-FITC second-
ary antibody. When HT29 cells were incubated with FITC–
RPMrel at 4jC, peptide binding appears to be confined to the
cell surface (Figure 5A). In contrast, incubating HT29 cells
with FITC–RPMrel at 37jC revealed the presence of diffuse
staining throughout the cells (Figure 5A). As HT29 cells have
little cytoplasm, it was difficult to distinguish between the cell
surface and the cytoplasm. In an attempt to determine the
subcellular localization of RPMrel, we incubated CaCo-2
cells, which have a larger percentage of cytoplasm, with
phage displaying the CPIEDRPMC peptide at 4jC or FITC–
RPMrel at 37jC. Analysis of the cells by fluorescent confocal
microscopy demonstrated that binding is confined to the cell
surface at 4jC, but in the cytoplasm at 37jC (Figure 5C). As
expected, FITC–RPMrel does not bind to HCT116 cells at
either 4jC or 37jC (Figure 5B).
Because FITC–RPMrel is internalized at 37jC, we rea-
soned that RPMrel may be able to deliver a toxin to HT29
Figure 5. RPMrel is internalized and able to selectively deliver a toxin to HT29 cells. (A and B) A well of HT29 or HCT116 cells was incubated with FITC–RPMrel
(green) at either 4 oC or 37 oC, fixed, and then incubated with GaFITC Alexa 488 (green) monoclonal antibody and Topro-3 nuclear stain. Slides were analyzed by
confocal microscopy (scale bar, 10 m). (C) A well of undifferentiated CaCo-2 cells was incubated with phage displaying the RPMrel peptide at 4 oC or the RPMrel
peptide at 37 oC, fixed, and then incubated with RaM13 antibody then GaR Alexa 488 secondary antibody and Topro-3 nuclear stain. Slides were analyzed by
confocal microscopy (scale bar, 10 m). (D) HT29 and HCT116 cells were incubated with increasing log concentrations of either RPMrel-D(KLAKLAK)2 or
D(KLAKLAK)2 for 72 hours at 37
oC: (n) HT29+RPMrel-D(KLAKLAK)2; ( w) HT29+D(KLAKLAK)2; (E) HCT116+RPMrel-D(KLAKLAK)2, and (j) HCT116+D(KLA-
KLAK)2. After incubation, cell viability was determined by MTT assay.
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cells. Ellerby et al. [17] described the use of a peptide isolated
from phage display, CNGRC, to deliver an antimicrobial
peptide toxin, D(KLAKLAK)2, to cells that bind the CNGRC
peptide. When CNGRC-GG-D(KLAKLAK)2 is internalized by
cells, the D(KLAKLAK)2 portion of the peptide binds to the
mitochondrial membrane, distorts the lipid matrix, and results
in the loss of transmembrane potential and apoptosis of the
cell [17]. In view of these results, we decided to couple
RPMrel to the mitochondrial toxin, D(KLAKLAK)2, and incu-
bate HT29 and HCT116 cells with either D(KLAKLAK)2 alone
or RPMrel-D(KLAKLAK)2. Cells were treated for 72 hours at
37jC. At the end of the incubation, cell viability was mea-
sured by MTT assay. As expected, incubation of either cell
line with D(KLAKLAK)2 alone did not affect the viability of the
cells (Figure 5D). Because RPMrel does not bind to HCT116
cells, we reasoned that HCT116 cells would be resistant to
death induced by RPMrel-D(KLAKLAK)2. This is indeed what
we observed for HCT116 incubation with RPMrel-D(KLA-
KLAK)2 (Figure 5D). In contrast, HT29 cell viability de-
creased by incubation with RPMrel-D(KLAKLAK)2 in a
concentration-dependent manner.
Discussion
The use of phage display libraries is a powerful method for
selecting peptides with desired binding properties [18]. In an
extension of this approach, we have developed a screening
protocol that uses selection and subtraction on intact, viable
cells, resulting in a peptide (RPMrel) that binds to colon
cancer.
Colon cancer–binding peptides as molecular probes for
in vivo imaging of early neoplastic disease could lead to early
diagnosis of colon cancer and, therefore, improved patient
survival. We believe that the identification of the peptide
RPMrel is promising for the development of such a colon
cancer diagnostic tool. The ability of RPMrel to bind colon
carcinoma samples from four patients but not to the sur-
rounding normal colon suggests that RPMrel is a potential
lead candidate in the development of an agent useful for
tumor diagnosis and imaging. However, in vivo models of
colon carcinoma must be used to fully determine colon
cancer selectivity and use of the peptide as a diagnostic
agent.
In addition to the potential as a diagnostic tool, peptides
that selectively bind and kill colon cancer cells, such as
RPMrel-D(KLAKLAK)2, have interesting potential therapeu-
tic implications. The coupling of peptides, such as RPMrel,
to apoptotic agents may produce a colon cancer–selective
agent with greatly reduced toxicity. In this vein, Arap et al.
[8] have shown that conjugating drugs to peptides selective
for angiogenic markers eliminated tumors in vivo by
destroying their vasculature. However, tumors under
1 mm3 can persist without a vasculature by receiving
nutrients from adjacent normal blood vessels, thus escap-
ing targeting of the vasculature [18]. Elimination of small
lesions may, therefore, require direct targeting of the tumor
cells. Peptides capable of tumor cell–selective delivery of
toxins may provide an important complement to antiangio-
genic strategies. Consistent with this, we have demonstrat-
ed that an RPMrel conjugate selectively killed colon cancer
cells in vitro. Based on these findings, further studies
characterizing the application of RPMrel to in vivo tumor
systems are warranted.
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